Introduction Intraventricular pressure gradient is regarded as a non-invasive indicator of
diastolic function. Salvianolic acid B (Sal-B), a traditional Asian medicine, revealed its …

Pressure overload diseases such as valvular stenosis and systemic hypertension
morphologically manifest in patients as cardiac concentric hypertrophy. Preventing cardiac …

Background Uremic cardiomyopathy (UC), the main cause of death in progressive chronic
kidney disease (CKD), is characterized by diastolic dysfunction. Intraventricular pressure …

Background It has been shown by various diagnostic methodologies that angiotensin
receptor blockage reduces left ventricular mass, improves diastolic function and increases …

Abstract Background Sacubitril/valsartan (S/V) has been shown to be an effective
antihypertensive drug combination. However, its therapeutic effects on blood pressure (BP) …

Sacubitril/valsartan has become an important first-line drug for symptomatic heart failure
(HF) patients, especially with left ventricular (LV) ejection fraction (LVEF)< 50%. However …

Background: Sacubitril/valsartan was shown to attenuate the development of cardiac
hypertrophy with enhanced blood pressure reduction compared with valsartan alone in …

Objective To elucidate the relationship between regression of hypertensive left ventricular
hypertrophy (LVH) and changes of coronary flow reserve (CFR). Methods Ninety-six …

Effects of Baicalin on Blood Pressure and Left Ventricular Remodeling in Rats with
Renovascular Hypertension - PMC Back to Top Skip to main content NIH NLM Logo Access …

Sacubitril/valsartan has been shown to improve clinical outcomes in patients with heart
failure and reduced ejection fraction (HFrEF), but its effects on left ventricular (LV) systolic …